

Bard1 Life Sciences Ltd

12:30 23 Mar 2017

BARD1 Life Sciences shares surge after positive ovarian cancer test

BARD1 Life Sciences (ASX:BD1) shares were trading 110% higher intra-day after successfully completing a clinical trial of its proprietary ovarian cancer diagnostic test.

The trial involving 348 samples (200 women with ovarian cancer and 148 controls) found the test to have both high specificity (87%) and high sensitivity (90%).

In addition, the test detected all subtypes and stages of ovarian cancer in the samples with the performance of the test between early-stage and late stage ovarian cancer not statistically different.

The BARD1 Ovarian Cancer Test is an ELISA-based blood test that uses a panel of peptides on a solid surface.

When exposed to a blood sample, the test measures the binding of antibodies in the patient's blood to these peptides.

Previous data from smaller scale studies had already established the proof of concept of the test and initial indications of high sensitivity and specificity.

With high levels of accuracy shown to all stages of ovarian cancer, the BARD1 test may offer a substantial improvement over existing ovarian cancer blood tests.

The test is expected to improve the accurate detection of cancer at all stages with few false positives.

Further studies are planned to demonstrate the use of the BARD1 Ovarian Cancer Test for distinction of benign ovarian lesions and cancer.

The company is also focused on its lead product, the BARD1 Lung Cancer Test, for early detection of lung cancer utilising novel tumour markers and a proprietary algorithm.

BARD1's closing cash balance as at 31 December 2016 was circa \$1.93 million.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security,

Price: \$0.03

Market Cap: \$46.48 m

1 Year Share Price Graph



September 2018 March 2019 September 2019

Share Information

Code: BD1

Listing: ASX

52 week High Low
0.0727632 0.00970176

Sector: Pharma & Biotech

Website: www.bard1.com

Company Synopsis:

Bard1 Life Sciences Ltd (ASX:BD1) is listed on the Australian Securities Exchange.

action@proactiveinvestors.com.au

portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.